# Highest Dose of Uproleselan in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Mixed Phenotype Acute Leukemia Relapsed or Refractory That Expresses E-selectin Ligand on the Cell Membrane

> **NCT05146739** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 8 (actual)

## Conditions studied

- Acute Myeloid Leukemia Post Cytotoxic Therapy
- Myelodysplastic Syndrome Post Cytotoxic Therapy
- Myeloid Leukemia Associated With Down Syndrome
- Recurrent Acute Myeloid Leukemia
- Recurrent Mixed Phenotype Acute Leukemia
- Recurrent Myelodysplastic Syndrome
- Refractory Acute Myeloid Leukemia
- Refractory Mixed Phenotype Acute Leukemia
- Refractory Myelodysplastic Syndrome

## Interventions

- **DRUG:** Cytarabine
- **DRUG:** Fludarabine
- **DRUG:** Leucovorin
- **DRUG:** Triple Intrathecal Chemotherapy
- **DRUG:** Uproleselan

## Key facts

- **NCT ID:** NCT05146739
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-10-10
- **Primary completion:** 2025-03-31
- **Final completion:** 2026-05-09
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2026-05-05

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05146739

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05146739, "Highest Dose of Uproleselan in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Mixed Phenotype Acute Leukemia Relapsed or Refractory That Expresses E-selectin Ligand on the Cell Membrane". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT05146739. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*